FY2026 EPS Estimate for Tenet Healthcare Boosted by Analyst

Key Points

• Zacks Research raised Tenet Healthcare’s FY2026 EPS estimate to $20.32 from $17.52 and maintained a “Strong-Buy” rating. The revised forecast is broadly aligned with the company’s FY2026 guidance of $20.30–$21.69 per share.
• Tenet’s latest quarterly results exceeded expectations, with EPS of $6.12 versus the $4.26 consensus and revenue of $6.04 billion, up 6.8% year over year.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and a $273 average price target, although insiders sold roughly $9.8 million of shares during the past quarter.

Tenet Healthcare Corporation (NYSE:THC - Free Report) - Investment analysts at Zacks Research raised their FY2026 earnings per share estimates for shares of Tenet Healthcare in a report issued on Thursday, August 13th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $20.32 for the year, up from their previous estimate of $17.52. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Tenet Healthcare's current full-year earnings is $20.97 per share. Zacks Research also issued estimates for Tenet Healthcare's Q4 2026 earnings at $5.04 EPS, Q2 2027 earnings at $4.66 EPS, Q3 2027 earnings at $4.50 EPS, Q4 2027 earnings at $5.13 EPS, FY2027 earnings at $18.91 EPS, Q2 2028 earnings at $5.35 EPS and FY2028 earnings at $20.09 EPS.

Several other equities analysts have also recently commented on THC. Barclays lifted their target price on shares of Tenet Healthcare from $240.00 to $271.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Mizuho set a $290.00 price target on Tenet Healthcare in a research report on Monday, August 10th. Royal Bank Of Canada boosted their price objective on Tenet Healthcare from $236.00 to $283.00 and gave the stock an "outperform" rating in a research report on Monday, July 27th. Guggenheim raised their target price on Tenet Healthcare from $242.00 to $283.00 and gave the company a "buy" rating in a research report on Tuesday, July 28th. Finally, KeyCorp lowered their target price on Tenet Healthcare from $250.00 to $225.00 and set an "overweight" rating on the stock in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $273.00.

Tenet Healthcare Stock Down 0.3%

Tenet Healthcare stock opened at $267.23 on Monday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.35 and a current ratio of 1.41. The stock has a market cap of $21.52 billion, a PE ratio of 10.31, a price-to-earnings-growth ratio of 1.02 and a beta of 1.23. Tenet Healthcare has a fifty-two week low of $157.58 and a fifty-two week high of $270.57. The firm's 50-day simple moving average is $210.20 and its 200 day simple moving average is $204.03.

Tenet Healthcare (NYSE:THC - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The firm had revenue of $6.04 billion for the quarter, compared to the consensus estimate of $5.43 billion. During the same period in the previous year, the firm earned $4.02 EPS. The business's revenue for the quarter was up 6.8% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS.

Insider Activity

In related news, Director Tammy Romo sold 2,500 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $260.83, for a total transaction of $652,075.00. Following the sale, the director owned 28,284 shares of the company's stock, valued at approximately $7,377,315.72. This represents a 8.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Lisa Y. Foo sold 10,000 shares of Tenet Healthcare stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $258.03, for a total value of $2,580,300.00. Following the transaction, the executive vice president directly owned 32,053 shares of the company's stock, valued at $8,270,635.59. The trade was a 23.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 41,375 shares of company stock valued at $9,793,347. 0.97% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tenet Healthcare

Large investors have recently modified their holdings of the company. Triumph Capital Management purchased a new stake in shares of Tenet Healthcare in the third quarter worth $25,000. Activest Wealth Management purchased a new position in Tenet Healthcare during the fourth quarter worth about $26,000. Elyxium Wealth LLC purchased a new stake in shares of Tenet Healthcare in the 4th quarter valued at about $29,000. Meeder Asset Management Inc. boosted its position in shares of Tenet Healthcare by 146.2% during the 4th quarter. Meeder Asset Management Inc. now owns 192 shares of the company's stock valued at $38,000 after acquiring an additional 114 shares during the last quarter. Finally, Trust Co. of Vermont purchased a new position in shares of Tenet Healthcare during the second quarter worth about $37,000. 95.44% of the stock is currently owned by institutional investors.

Tenet Healthcare News Roundup

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: An analyst boosted Tenet’s third-quarter EPS forecast, signaling improving expectations for the company’s near-term profitability. Q3 EPS Forecast for Tenet Healthcare Boosted by Analyst
• Positive Sentiment: Zacks Research raised its Tenet EPS estimates across multiple periods: fourth-quarter 2026 EPS increased to $5.04 from $4.47, fiscal 2026 EPS to $20.32 from $17.52, fiscal 2027 EPS to $18.91 from $17.17, and fiscal 2028 EPS to $20.09 from $17.99. Quarterly estimates for Q2 2027, Q3 2027, Q4 2027 and Q2 2028 were also increased. Zacks maintained a “Strong-Buy” rating, supporting the bullish outlook for earnings growth.
• Neutral Sentiment: The revised fiscal 2026 estimate of $20.32 remains below the broader analyst consensus of $21.07, suggesting that Zacks’ revisions are favorable but do not represent an across-the-board increase in expectations.
• Neutral Sentiment: Wall Street Zen downgraded Tenet from “Strong Buy” to “Buy.” Although the stock remains positively rated, the change reflects somewhat less conviction and could limit the impact of the otherwise favorable earnings revisions. Wall Street Zen Downgrades Tenet Healthcare to Buy

About Tenet Healthcare

Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source